• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.

作者信息

Ruella M, Kenderian S S, Shestova O, Klichinsky M, Melenhorst J J, Wasik M A, Lacey S F, June C H, Gill S

机构信息

Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

出版信息

Leukemia. 2017 Jan;31(1):246-248. doi: 10.1038/leu.2016.262. Epub 2016 Sep 28.

DOI:10.1038/leu.2016.262
PMID:27677739
Abstract
摘要

相似文献

1
Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.激酶抑制剂依鲁替尼用于预防抗CD19嵌合抗原受体T细胞治疗B细胞肿瘤后发生的细胞因子释放综合征。
Leukemia. 2017 Jan;31(1):246-248. doi: 10.1038/leu.2016.262. Epub 2016 Sep 28.
2
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.表达 CD19/CD20 双特异性嵌合抗原受体的 T 细胞可防止恶性 B 细胞发生抗原逃逸。
Cancer Immunol Res. 2016 Jun;4(6):498-508. doi: 10.1158/2326-6066.CIR-15-0231. Epub 2016 Apr 8.
3
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.依鲁替尼治疗失败后，用CD19特异性嵌合抗原受体修饰的T细胞治疗慢性淋巴细胞白血病的持久分子缓解。
J Clin Oncol. 2017 Sep 10;35(26):3010-3020. doi: 10.1200/JCO.2017.72.8519. Epub 2017 Jul 17.
4
[Adoptive immunotherapy utilizing anti-CD19 chimeric antigen receptor T-cells for B-cell malignancies].利用抗CD19嵌合抗原受体T细胞治疗B细胞恶性肿瘤的过继性免疫疗法
Rinsho Ketsueki. 2016;57(11):2365-2372. doi: 10.11406/rinketsu.57.2365.
5
Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.CD22/CD19 嵌合抗原受体 T 细胞疗法治疗累及胃肠道的复发/难治性侵袭性 B 细胞淋巴瘤患者的疗效和毒性。
Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13.
6
Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.新型抗CD19嵌合抗原受体的构建及转导T细胞的抗白血病功能研究
Oncotarget. 2016 Mar 1;7(9):10638-49. doi: 10.18632/oncotarget.7079.
7
Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.抗CD19嵌合抗原受体T细胞疗法治疗B细胞非霍奇金淋巴瘤的临床研究进展
Cancer Sci. 2017 Jun;108(6):1109-1118. doi: 10.1111/cas.13239. Epub 2017 May 25.
8
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.新型含人源可变区的抗 CD19 嵌合抗原受体的功能受铰链和跨膜结构域影响。
Mol Ther. 2017 Nov 1;25(11):2452-2465. doi: 10.1016/j.ymthe.2017.07.013. Epub 2017 Jul 27.
9
CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.CD20-CD19 双特异性 CAR T 细胞治疗 B 细胞恶性肿瘤。
Hum Gene Ther. 2017 Dec;28(12):1147-1157. doi: 10.1089/hum.2017.126.
10
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.伊布替尼可增强嵌合抗原受体T细胞在白血病中的植入及疗效。
Blood. 2016 Mar 3;127(9):1117-27. doi: 10.1182/blood-2015-11-679134. Epub 2016 Jan 26.

引用本文的文献

1
Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors.嵌合抗原受体T细胞（CAR-T）疗法在血液系统肿瘤和实体瘤治疗中的当前进展与挑战
Immunotargets Ther. 2025 Jun 27;14:655-680. doi: 10.2147/ITT.S519616. eCollection 2025.
2
Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis related to CAR-T cell therapies.嵌合抗原受体T细胞（CAR-T）疗法相关的细胞因子释放综合征、神经毒性和噬血细胞性淋巴组织细胞增生症的发病机制及管理策略的最新进展
Ann Hematol. 2025 Jun 19. doi: 10.1007/s00277-025-06467-y.
3
Promising Targeted Therapies for Hemophagocytic Lymphohistiocytosis: A Translational Perspective Based on Immunopathology.

本文引用的文献

1
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.用于B细胞肿瘤的嵌合抗原受体T细胞：为您选择合适的嵌合抗原受体
Curr Hematol Malig Rep. 2016 Oct;11(5):368-84. doi: 10.1007/s11899-016-0336-z.
2
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.急性淋巴细胞白血病嵌合抗原受体T细胞治疗后细胞因子释放综合征预测生物标志物的鉴定
Cancer Discov. 2016 Jun;6(6):664-79. doi: 10.1158/2159-8290.CD-16-0040. Epub 2016 Apr 13.
3
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
噬血细胞性淋巴组织细胞增生症的有前景的靶向治疗：基于免疫病理学的转化视角
Clin Rev Allergy Immunol. 2025 Jun 9;68(1):56. doi: 10.1007/s12016-025-09068-9.
4
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review.利用依鲁替尼的免疫调节潜力改善B细胞恶性肿瘤T细胞介导疗法的疗效：一项叙述性综述
Target Oncol. 2025 Mar;20(2):217-234. doi: 10.1007/s11523-025-01133-9. Epub 2025 Mar 4.
5
Novel strategies to manage CAR-T cell toxicity.管理嵌合抗原受体T细胞毒性的新策略。
Nat Rev Drug Discov. 2025 May;24(5):379-397. doi: 10.1038/s41573-024-01100-5. Epub 2025 Feb 3.
6
Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors.嵌合抗原受体T细胞疗法的进展：抗原选择、修饰及实体瘤的当前试验
Front Immunol. 2025 Jan 6;15:1489827. doi: 10.3389/fimmu.2024.1489827. eCollection 2024.
7
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.乘风破浪：CAR-T 细胞疗法中细胞因子相关毒性的管理。
Semin Immunopathol. 2024 Jul 16;46(3-4):5. doi: 10.1007/s00281-024-01013-w.
8
CAR-T Cells in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病中的嵌合抗原受体T细胞
Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024045. doi: 10.4084/MJHID.2024.045. eCollection 2024.
9
Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them.推进慢性淋巴细胞白血病的嵌合抗原受体T细胞疗法：探索耐药机制及克服这些机制的创新策略。
Cancer Drug Resist. 2024 May 14;7:18. doi: 10.20517/cdr.2023.100. eCollection 2024.
10
Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies.自体 CAR T 细胞制造失败和/或血液系统恶性肿瘤疗效的早期预测因素。
Blood Adv. 2024 Jan 23;8(2):337-342. doi: 10.1182/bloodadvances.2023011992.
伊布替尼联合抗 CD19 嵌合抗原受体 T 细胞（CART19）可改善套细胞淋巴瘤的应答。
Clin Cancer Res. 2016 Jun 1;22(11):2684-96. doi: 10.1158/1078-0432.CCR-15-1527. Epub 2016 Jan 27.
4
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.伊布替尼可增强嵌合抗原受体T细胞在白血病中的植入及疗效。
Blood. 2016 Mar 3;127(9):1117-27. doi: 10.1182/blood-2015-11-679134. Epub 2016 Jan 26.
5
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.布鲁顿酪氨酸激酶（BTK）和白细胞介素-2诱导激酶（ITK）的抑制剂依鲁替尼可增强检查点阻断的治疗性抗肿瘤免疫。
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E966-72. doi: 10.1073/pnas.1500712112. Epub 2015 Feb 17.
6
Chimeric antigen receptor T cells for sustained remissions in leukemia.用于白血病持续缓解的嵌合抗原受体T细胞。
N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222.
7
Current concepts in the diagnosis and management of cytokine release syndrome.细胞因子释放综合征的诊断和治疗的当前概念。
Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29.
8
Managing cytokine release syndrome associated with novel T cell-engaging therapies.管理与新型T细胞接合疗法相关的细胞因子释放综合征。
Cancer J. 2014 Mar-Apr;20(2):119-22. doi: 10.1097/PPO.0000000000000035.
9
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.依鲁替尼可拮抗利妥昔单抗依赖的自然杀伤细胞介导的细胞毒性作用。
Blood. 2014 Mar 20;123(12):1957-60. doi: 10.1182/blood-2014-01-547869.
10
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.19-28z嵌合抗原受体T细胞疗法治疗B细胞急性淋巴细胞白血病的疗效及毒性管理
Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.